Many domestic API companies boast ample production capacity, and whether such capacity can be fully utilized determines the value ceiling of API enterprises. Leading API companies represented by Apeloa Pharmaceutical and Jiuzhou Pharmaceutical have successfully built an integrated layout covering API + Finished Dosage Form + CDMO, expanding their business portfolios.
The integrated model of API + Finished Dosage Form has evolved from an optional strategy into the industry mainstream. This trend is primarily driven by dual pressures from policies and the market: global pharmaceutical cost-control policies (such as volume-based procurement in China) have put downward pressure on end drug prices. Mastering upstream API resources has become a lifeline for pharmaceutical preparation enterprises to control costs and ensure supply chain stability. For API manufacturers, downstream business extension is an inevitable choice to secure higher profits and hedge against market volatility. Going forward, pure preparation enterprises without self-owned core API support will see a marked decline in competitiveness.
Apeloa Pharmaceutical and Jiuzhou Pharmaceutical made early strategic layouts in the integrated business of API, finished dosage form and CDMO, building upstream and downstream linkage across the pharmaceutical industrial chain to withstand risks arising from industry cyclical fluctuations.
Chinese CDMO firms have evolved into the world's pharmaceutical industrial chain foundries. Top-tier API companies naturally extend into CDMO services by leveraging their internationally GMP-certified production capacity, mature EHS management systems, and professional chemical synthesis capabilities. This move not only improves capacity utilization and return on assets, but more importantly, enables the business model upgrade from product selling to technology and service output. With continuous rising investment in innovative drug R&D and the growing tendency of pharmaceutical enterprises to outsource R&D and production, API companies with strong technical strength will capture high-value-added growth opportunities in the CDMO track.
